Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08JWJ
|
|||
| Former ID |
DCL000593
|
|||
| Drug Name |
PF-1228305
|
|||
| Synonyms |
Sitaxentan sodium; Sitaxsentan sodium
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pulmonary hypertension [ICD-11: BB01; ICD-10: I27, I27.0; ICD-9: 416] | Phase 3 | [1] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H14ClN2NaO6S2
|
|||
| Canonical SMILES |
CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)[N-]C4=C(C(=NO4)C)Cl)OCO2.[Na+]
|
|||
| InChI |
1S/C18H14ClN2O6S2.Na/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18;/h3-5,7H,6,8H2,1-2H3;/q-1;+1
|
|||
| InChIKey |
MDTNUYUCUYPIHE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 210421-74-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
12015041, 15318680, 16577869, 23613118, 43529705, 50386535, 50386536, 57376728, 135110232, 152159714, 152258321, 160647160, 160692699, 163124765, 164117708, 164233699, 174528310, 179322759, 185971399, 196108027, 198980810, 204360314, 215771094, 225848332, 241051997, 249828035, 252057354, 252110245, 252451460
|
|||
| SuperDrug ATC ID |
C02KX03
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Endothelin A receptor (EDNRA) | Target Info | Antagonist | [1] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Renin secretion | ||||
| Pathways in cancer | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Endothelin signaling pathway | |||
| Pathway Interaction Database | Endothelins | |||
| EGFR-dependent Endothelin signaling events | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pfizer. Product Development Pipeline. March 31 2009. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.